These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 36535950)

  • 1. Paliperidone palmitate vs. paliperidone extended-release for the acute treatment of adults with schizophrenia: a systematic review and pairwise and network meta-analysis.
    Kishi T; Sakuma K; Iwata N
    Transl Psychiatry; 2022 Dec; 12(1):519. PubMed ID: 36535950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paliperidone extended release: a review of its use in the management of schizophrenia.
    Chwieduk CM; Keating GM
    Drugs; 2010 Jul; 70(10):1295-317. PubMed ID: 20568835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies.
    Meltzer HY; Bobo WV; Nuamah IF; Lane R; Hough D; Kramer M; Eerdekens M
    J Clin Psychiatry; 2008 May; 69(5):817-29. PubMed ID: 18466043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study.
    Davidson M; Emsley R; Kramer M; Ford L; Pan G; Lim P; Eerdekens M
    Schizophr Res; 2007 Jul; 93(1-3):117-30. PubMed ID: 17466492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of paliperidone extended-release in schizophrenia patients with prominent affective symptoms.
    Canuso CM; Turkoz I; Sheehan JJ; Bossie CA
    J Affect Disord; 2010 Jan; 120(1-3):193-9. PubMed ID: 19552963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paliperidone extended release: in adolescents with schizophrenia.
    Perry CM
    Paediatr Drugs; 2012 Dec; 14(6):417-27. PubMed ID: 23050744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis.
    Turkoz I; Bossie CA; Lindenmayer JP; Schooler N; Canuso CM
    BMC Psychiatry; 2011 Feb; 11():21. PubMed ID: 21299844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia.
    Canuso CM; Dirks B; Carothers J; Kosik-Gonzalez C; Bossie CA; Zhu Y; Damaraju CV; Kalali AH; Mahmoud R
    Am J Psychiatry; 2009 Jun; 166(6):691-701. PubMed ID: 19411369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of paliperidone extended release on the symptoms and functioning of schizophrenia.
    Huang MW; Yang TT; Ten PR; Su PW; Wu BJ; Chan CH; Lan TH; Liu IC; Chiu WC; Li CY; Cheng KS; Yeh YC
    BMC Clin Pharmacol; 2012 Jan; 12():1. PubMed ID: 22225965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study.
    Marder SR; Kramer M; Ford L; Eerdekens E; Lim P; Eerdekens M; Lowy A
    Biol Psychiatry; 2007 Dec; 62(12):1363-70. PubMed ID: 17601495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended-release paliperidone: efficacy, safety and tolerability profile of a new atypical antipsychotic.
    Owen RT
    Drugs Today (Barc); 2007 Apr; 43(4):249-58. PubMed ID: 17460786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial.
    Bossie CA; Sliwa JK; Ma YW; Fu DJ; Alphs L
    BMC Psychiatry; 2011 May; 11():79. PubMed ID: 21569242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial.
    Kane J; Canas F; Kramer M; Ford L; Gassmann-Mayer C; Lim P; Eerdekens M
    Schizophr Res; 2007 Feb; 90(1-3):147-61. PubMed ID: 17092691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia.
    Fowler JA; Bettinger TL; Argo TR
    Clin Ther; 2008 Feb; 30(2):231-48. PubMed ID: 18343262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of paliperidone ER and other oral atypical antipsychotics in schizophrenia.
    Jones MP; Nicholl D; Trakas K
    Int J Clin Pharmacol Ther; 2010 Jun; 48(6):383-99. PubMed ID: 20497747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
    Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
    Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens.
    Fu DJ; Bossie CA; Kern Sliwa J; Ma YW; Alphs L
    Clin Schizophr Relat Psychoses; 2014 Jul; 8(2):101-9, 109A. PubMed ID: 23446197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paliperidone extended-release for schizophrenia: effects on symptoms and functioning in acutely ill patients with negative symptoms.
    Canuso CM; Bossie CA; Turkoz I; Alphs L
    Schizophr Res; 2009 Aug; 113(1):56-64. PubMed ID: 19560322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension.
    Tzimos A; Samokhvalov V; Kramer M; Ford L; Gassmann-Mayer C; Lim P; Eerdekens M
    Am J Geriatr Psychiatry; 2008 Jan; 16(1):31-43. PubMed ID: 18165460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching from oral risperidone to flexibly dosed oral paliperidone extended-release: core symptoms, satisfaction, and quality of life in patients with stable but symptomatic schizophrenia: the RISPALI study.
    Gattaz WF; Campos JA; Lacerda AL; Henna E; Ruschel SI; Bressan RA; de Oliveira IR; Rocha FL; Grabowski HM; Sacomani E; Louzã MR; Quevedo J; Elkis H; Zorzetto Filho D; Périco Cde A; Lawson FL; Appolinário JC
    Curr Med Res Opin; 2014 Apr; 30(4):695-709. PubMed ID: 24289141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.